Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

BiopharmaTrend Blog


Aigenpulse introduces novel data intelligence platform to life science markets

   by Alice Chamberlain
posted in News

Life science and data technology innovator, Aigenpulse, is introducing a new state of-the-art data intelligence platform which is designed to expedite the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced analytics to underpin scientific decision making.

TrialScope Expands Leadership Team with New Chief Commercial Officer

   by Darcy Grabenstein
posted in News
TrialScope Expands Leadership Team with New Chief Commercial Officer

Chris Venezia to Leverage His Expertise in Healthcare Technology

TrialScope, the global leader in clinical trial transparency, has hired Chris Venezia as Chief Commercial Officer, expanding its executive team.

Much of Venezia’s career has been focused on pharmaceutical and healthcare technologies. A frequent speaker and trainer, he served as Chief Revenue Officer of Signals Analytics. Prior to that, he worked in global sales at both Clarivate Analytics and Thomson Reuters, and served as vice president of sales at GlobalData Plc.

Major VC Rounds For AI-driven Biotechs in 2020

Major VC Rounds For AI-driven Biotechs in 2020

The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- according to data by PitchBook biopharma venture deals in 2020 are down roughly 16% compared to last year. 

However, there is still a lot going on in drug discovery and healthcare, and here I would like to specifically focus on artificial intelligence (AI)-driven biotech and health tech startups who managed to raise notable rounds in 2020, so far (based on our report “A Landscape of Artificial Intelligence (AI) In Drug Discovery and Development”). The deals are ordered by the amount of money raised 

[Interview] How COVID-19 Catalyzed AI-assisted Open Science Drug Discovery

[Interview] How COVID-19 Catalyzed AI-assisted Open Science Drug Discovery

Biopharma companies are now racing to find much-needed cures against SARS-CoV-2, a virus that caused the largest global pandemic of our time. One notable effort is the COVID Moonshot project, organized by an international consortium of scientists from academia, biotechs, contract research organizations (CROs), and pharma -- all working pro bono or via crowdfunding, philanthropy, and grants. 

The aim of the project is to rapidly develop easily manufacturable antiviral drugs that can inhibit the SARS-CoV-2 main protease, which is believed to be an Achilles heel of the coronavirus. The project is managed by PostEra, a startup company that uses artificial intelligence (AI) algorithms to map routes for chemical synthesis to speed the drug-discovery process.

FDA Analysis of Antibiotic Development - with Hubris!

FDA Analysis of Antibiotic Development - with Hubris!
(This post originally appeared on David Shlaes's personal blog)
 
The US FDA just published an analysis of antibiotic development looking back over the last 40 years. The paper was accompanied by an editorial by Rex and Outterson. These papers are well worth reading and I highly recommend them for everyone whether they are familiar with antibiotic development or not. I must say that the hubris of the FDA analysis is astounding (see below).